Is INFE.PA stock a buy today?

INFE.PA stock looks like a tactical buy for short-term traders if price dips toward **€66.00–€66.50** with tight stops. For investors, Meyka AI assigns a **B/HOLD** grade and advises further due diligence on earnings and liquidity.

What are the key support and resistance levels for INFE.PA stock?

Support sits near the 200-day average **€65.85** and the year low **€50.50**. Near-term resistance is the 50-day average **€75.04** and congestion around **€80.00**. Use these levels for entry, target, and stop placement.

How reliable is Meyka AI's INFE.PA stock forecast?

Meyka AI's forecast model projects **€74.29** in 1 year and longer-term targets. These are probabilistic model outputs and not guarantees. Combine forecasts with earnings checks and liquidity assessment before trading.

What financial metrics matter most for INFE.PA stock?

Watch **EPS €6.35**, trailing **PE 11.18**, cash per share **€29.94**, and dividend per share **€11.33**. Also monitor receivables cycle (DSO **152.94 days**) and free cash flow yield when assessing sustainability.

EU Stocks

Pre-market 06 Feb 2026: INFE.PA Compagnie Industrielle et Financière d’Entreprises SA EURONEXT €71.00 oversold bounce: possible rebound near €65.85

ByDanny Kontos February 6, 2026February 6, 2026

The INFE.PA stock opens pre-market on 06 Feb 2026 at €71.00, signalling a potential oversold bounce after a 3-month drop of -14.46%. Traders should note thin liquidity with volume 16 and average volume 85, which increases volatility risk on rebounds. We outline a tactical bounce plan, support and resistance levels, valuation checks, and a Meyka AI forecast to frame short-term trade ideas.